(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the Society of Urologic Oncology (SUO) Session. Dr. Bernard ...

Dr. Huang concluded this presentation discussing results of a phase II study of tislelizumab as neoadjuvant treatment for cisplatin-ineligible high-risk upper tract urothelial carcinoma with the ...

Dr. Kazuyuki Numakura presented a study of primary resistance to nivolumab + ipilimumab therapy affecting second-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients. Long-term ...

Of the 422 patients, 198 (47%) experienced a recurrence following surgery. There was an almost even split between early (34%), mid (33%), and late recurrences (32%). Time to recurrence was associated ...

(UroToday.com) The American Urological Association (AUA) 2025 Annual Meeting, held in Las Vegas, NV, was host to an advanced prostate cancer podium session. Dr. Alejandro Sanchez presented the results ...

Each patient underwent sequential laser activation in three commonly used modes: fragmentation (low power), dusting (moderate power), and pop-dusting (high power), with temperatures recorded ...

Michael Creswell, PGY-3 from the University of Kansas, presented findings from the AUA Medical Student Survey, analyzing changes in the urology residency application process from 2022 to 2024. Against ...

The SOPHIA study retrospectively investigated the first-in-man safety and efficacy in 6 patients with stress urinary incontinence who received the UroActive TM device. Results from the primary ...

Minh Nguyen, MS2, from the Brody School of Medicine at East Carolina University, presented findings on the evolving trends in pelvic lymph node dissection (PLND) during radical prostatectomy. Her ...

Diagnostic Accuracy of Combination of Multiparametric MRI PI-RADS Score v2.1 and Prostate-Specific Antigen Density for Prostate Cancer Detection. April 9, 2025 Fast prostate MRI vs. conventional ...

Nauseef JT, Sun MP, Thomas C, et al. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer in patients with prior treatment with ...

The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025, in Las Vegas, Nevada, was host to the Moderated Poster 13: Prostate Cancer: Staging Session. Dr. Claudia Kesch ...